60 Degrees Pharmaceuticals Advances B-Free Study for Babesiosis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 02 2026
0mins
Source: NASDAQ.COM
- Study Progress: 60 Degrees Pharmaceuticals announced that an independent Data Safety Monitoring Board has recommended continuing the B-Free chronic Babesiosis study after reviewing safety data from the first six patients at Day 30, indicating feasibility and safety of the trial.
- Patient Recruitment Plan: The company plans to enroll up to 100 patients with confirmed Babesia infection, utilizing FDA-licensed RNA amplification tests and two CLIA-validated RT-PCR assays for screening to ensure accuracy and efficacy of the study.
- Treatment Regimen: The B-Free trial employs the ARAKODA regimen, which includes a 12-week self-administered oral treatment of 200 mg daily for the first four days, followed by 200 mg weekly, aimed at assessing recovery from fatigue, with the primary endpoint being fatigue resolution at Day 90.
- Market Performance: SXTP shares have traded between $1.22 and $10.77 over the past year, closing at $1.75 on Wednesday, down 0.57%, reflecting cautious market sentiment regarding the study's outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SXTP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SXTP
Wall Street analysts forecast SXTP stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 1.620
Low
3.40
Averages
3.40
High
3.40
Current: 1.620
Low
3.40
Averages
3.40
High
3.40
About SXTP
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
60 Degrees Pharmaceuticals Advances B-Free Study for Babesiosis
- Study Progress: 60 Degrees Pharmaceuticals announced that an independent Data Safety Monitoring Board has recommended continuing the B-Free chronic Babesiosis study after reviewing safety data from the first six patients at Day 30, indicating feasibility and safety of the trial.
- Patient Recruitment Plan: The company plans to enroll up to 100 patients with confirmed Babesia infection, utilizing FDA-licensed RNA amplification tests and two CLIA-validated RT-PCR assays for screening to ensure accuracy and efficacy of the study.
- Treatment Regimen: The B-Free trial employs the ARAKODA regimen, which includes a 12-week self-administered oral treatment of 200 mg daily for the first four days, followed by 200 mg weekly, aimed at assessing recovery from fatigue, with the primary endpoint being fatigue resolution at Day 90.
- Market Performance: SXTP shares have traded between $1.22 and $10.77 over the past year, closing at $1.75 on Wednesday, down 0.57%, reflecting cautious market sentiment regarding the study's outcomes.
See More
60 Degrees Pharmaceuticals Signs Patent Licensing Agreement with Florida State University
- Patent Licensing Agreement: 60 Degrees Pharmaceuticals has signed a patent licensing agreement with Florida State University to support large-scale production of castanospermine, a key ingredient for developing Australian Chestnut Extract aimed at non-prescription and dietary supplement markets.
- Market Potential: This agreement enables 60 Degrees Pharmaceuticals to leverage research from Florida State University, enhancing its competitiveness in the dietary supplement sector and potentially generating new revenue streams for the company.
- FDA Feedback Meeting: The company plans to meet with the FDA on July 1, 2026, to discuss safety requirements related to its new dietary ingredient notification (NDIN) filing, ensuring compliance before submitting a revised application to expedite product launch.
- Strategic Development Direction: By collaborating with Florida State University, 60 Degrees Pharmaceuticals not only strengthens its R&D capabilities but also positions itself favorably in the growing health products market, further advancing its long-term growth strategy.
See More
60 Degrees Pharmaceuticals Initiates Tafenoquine Clinical Study for Babesiosis
- Clinical Study Launch: 60 Degrees Pharmaceuticals announced the early enrollment of the first patient in a clinical study evaluating Tafenoquine for treating babesiosis, indicating smooth progress and potential for ahead-of-schedule patient recruitment.
- Study Design: This randomized, double-blind, placebo-controlled trial plans to enroll up to 24 patients with babesiosis, primarily assessing clinical symptom resolution and parasite clearance, with interim analyses expected 50 days after enrollment completion.
- Drug Background: Tafenoquine is an anti-malarial agent that received FDA approval in 2018 for malaria prophylaxis and is currently available in the U.S. and Australia, showcasing its potential in new indications.
- Future Outlook: With early enrollment progress, the study aims to meet minimal recruitment by July 2026, while Tafenoquine is also being evaluated in a Phase 2 trial for babesiosis, with topline results expected in the second quarter of this year.
See More
60 Degrees Pharmaceuticals FY 2025 Earnings Report Analysis
- Disappointing Earnings: 60 Degrees Pharmaceuticals reported a FY 2025 GAAP EPS of -$11.73, missing expectations by $4.83, indicating ongoing challenges in profitability that could undermine investor confidence.
- Lackluster Revenue Growth: The company achieved revenue of $1 million, a 63.9% year-over-year increase, yet it fell short of the $1.05 million forecast, suggesting that despite growth, it failed to meet market expectations, potentially impacting future financing capabilities.
- Slight Gross Profit Increase: Gross profit for 2025 was approximately $223.8 thousand, up from $222.8 thousand in 2024, reflecting efforts in cost control, yet overall profitability remains weak.
- Cautious Market Reaction: Given the earnings report's failure to meet expectations, investors are likely to adopt a cautious stance towards 60 Degrees Pharmaceuticals' future prospects, which may lead to stock price volatility and decreased market confidence.
See More
60 Degrees Pharmaceuticals Submits New Dietary Ingredient Notification for Australian Chestnut Extract
- FDA Notification Deadline: 60 Degrees Pharmaceuticals submitted a New Dietary Ingredient Notification for Australian Chestnut Extract to the FDA on March 11, 2026, with a deadline for objections set for May 25, 2026, after which the company can freely market the supplement, potentially opening new market opportunities.
- License Agreement Expansion: The company has signed an option agreement with Florida State University to license rights related to new capsule formulation methods, building on its January 2026 exclusive rights acquisition for large-scale purification of Castanospermine, indicating ongoing investment in product development.
- Scientific Basis Support: The primary component of Australian Chestnut Extract, Castanospermine, has shown in animal models to impact disease outcomes and modulate carbohydrate metabolism at low doses, providing a scientific foundation for future clinical applications and enhancing the market competitiveness of the company's products.
- Company Background: Founded in 2010, 60 Degrees Pharmaceuticals focuses on developing new medicines for vector-borne diseases, with its lead product ARAKODA receiving FDA approval in 2018 and currently available in the U.S. and Australia, demonstrating the company's solid position and growth potential in the industry.
See More
60 Degrees Pharmaceuticals Stock Price Fluctuation Analysis
- Stock Price Movement: 60 Degrees Pharmaceuticals saw a 7.90% decline in premarket trading at $2.68 after a 9.6% drop on Thursday, indicating market concerns regarding its recent performance.
- Clinical Trial Success: The company reported a nearly 100% cure rate in its babesiosis trial with tafenoquine treatment, providing strong support for its future market potential and positioning it favorably against competitors.
- Partnership Expansion: 60 Degrees Pharmaceuticals partnered with Runway Health to enhance pre-departure access to ARAKODA through a travel health platform, allowing international travelers to obtain physician-led online consultations, thereby increasing its market penetration.
- Analyst Ratings: The stock carries a Buy rating with an average price target of $17.60, with HC Wainwright & Co. raising its target to $24.00, reflecting analysts' confidence in the company's growth prospects.
See More
60 Degrees Pharmaceuticals Advances B-Free Study for Babesiosis
- Study Progress: 60 Degrees Pharmaceuticals announced that an independent Data Safety Monitoring Board has recommended continuing the B-Free chronic Babesiosis study after reviewing safety data from the first six patients at Day 30, indicating feasibility and safety of the trial.
- Patient Recruitment Plan: The company plans to enroll up to 100 patients with confirmed Babesia infection, utilizing FDA-licensed RNA amplification tests and two CLIA-validated RT-PCR assays for screening to ensure accuracy and efficacy of the study.
- Treatment Regimen: The B-Free trial employs the ARAKODA regimen, which includes a 12-week self-administered oral treatment of 200 mg daily for the first four days, followed by 200 mg weekly, aimed at assessing recovery from fatigue, with the primary endpoint being fatigue resolution at Day 90.
- Market Performance: SXTP shares have traded between $1.22 and $10.77 over the past year, closing at $1.75 on Wednesday, down 0.57%, reflecting cautious market sentiment regarding the study's outcomes.
See More
60 Degrees Pharmaceuticals Signs Patent Licensing Agreement with Florida State University
- Patent Licensing Agreement: 60 Degrees Pharmaceuticals has signed a patent licensing agreement with Florida State University to support large-scale production of castanospermine, a key ingredient for developing Australian Chestnut Extract aimed at non-prescription and dietary supplement markets.
- Market Potential: This agreement enables 60 Degrees Pharmaceuticals to leverage research from Florida State University, enhancing its competitiveness in the dietary supplement sector and potentially generating new revenue streams for the company.
- FDA Feedback Meeting: The company plans to meet with the FDA on July 1, 2026, to discuss safety requirements related to its new dietary ingredient notification (NDIN) filing, ensuring compliance before submitting a revised application to expedite product launch.
- Strategic Development Direction: By collaborating with Florida State University, 60 Degrees Pharmaceuticals not only strengthens its R&D capabilities but also positions itself favorably in the growing health products market, further advancing its long-term growth strategy.
See More
60 Degrees Pharmaceuticals Initiates Tafenoquine Clinical Study for Babesiosis
- Clinical Study Launch: 60 Degrees Pharmaceuticals announced the early enrollment of the first patient in a clinical study evaluating Tafenoquine for treating babesiosis, indicating smooth progress and potential for ahead-of-schedule patient recruitment.
- Study Design: This randomized, double-blind, placebo-controlled trial plans to enroll up to 24 patients with babesiosis, primarily assessing clinical symptom resolution and parasite clearance, with interim analyses expected 50 days after enrollment completion.
- Drug Background: Tafenoquine is an anti-malarial agent that received FDA approval in 2018 for malaria prophylaxis and is currently available in the U.S. and Australia, showcasing its potential in new indications.
- Future Outlook: With early enrollment progress, the study aims to meet minimal recruitment by July 2026, while Tafenoquine is also being evaluated in a Phase 2 trial for babesiosis, with topline results expected in the second quarter of this year.
See More
60 Degrees Pharmaceuticals FY 2025 Earnings Report Analysis
- Disappointing Earnings: 60 Degrees Pharmaceuticals reported a FY 2025 GAAP EPS of -$11.73, missing expectations by $4.83, indicating ongoing challenges in profitability that could undermine investor confidence.
- Lackluster Revenue Growth: The company achieved revenue of $1 million, a 63.9% year-over-year increase, yet it fell short of the $1.05 million forecast, suggesting that despite growth, it failed to meet market expectations, potentially impacting future financing capabilities.
- Slight Gross Profit Increase: Gross profit for 2025 was approximately $223.8 thousand, up from $222.8 thousand in 2024, reflecting efforts in cost control, yet overall profitability remains weak.
- Cautious Market Reaction: Given the earnings report's failure to meet expectations, investors are likely to adopt a cautious stance towards 60 Degrees Pharmaceuticals' future prospects, which may lead to stock price volatility and decreased market confidence.
See More
60 Degrees Pharmaceuticals Submits New Dietary Ingredient Notification for Australian Chestnut Extract
- FDA Notification Deadline: 60 Degrees Pharmaceuticals submitted a New Dietary Ingredient Notification for Australian Chestnut Extract to the FDA on March 11, 2026, with a deadline for objections set for May 25, 2026, after which the company can freely market the supplement, potentially opening new market opportunities.
- License Agreement Expansion: The company has signed an option agreement with Florida State University to license rights related to new capsule formulation methods, building on its January 2026 exclusive rights acquisition for large-scale purification of Castanospermine, indicating ongoing investment in product development.
- Scientific Basis Support: The primary component of Australian Chestnut Extract, Castanospermine, has shown in animal models to impact disease outcomes and modulate carbohydrate metabolism at low doses, providing a scientific foundation for future clinical applications and enhancing the market competitiveness of the company's products.
- Company Background: Founded in 2010, 60 Degrees Pharmaceuticals focuses on developing new medicines for vector-borne diseases, with its lead product ARAKODA receiving FDA approval in 2018 and currently available in the U.S. and Australia, demonstrating the company's solid position and growth potential in the industry.
See More
60 Degrees Pharmaceuticals Stock Price Fluctuation Analysis
- Stock Price Movement: 60 Degrees Pharmaceuticals saw a 7.90% decline in premarket trading at $2.68 after a 9.6% drop on Thursday, indicating market concerns regarding its recent performance.
- Clinical Trial Success: The company reported a nearly 100% cure rate in its babesiosis trial with tafenoquine treatment, providing strong support for its future market potential and positioning it favorably against competitors.
- Partnership Expansion: 60 Degrees Pharmaceuticals partnered with Runway Health to enhance pre-departure access to ARAKODA through a travel health platform, allowing international travelers to obtain physician-led online consultations, thereby increasing its market penetration.
- Analyst Ratings: The stock carries a Buy rating with an average price target of $17.60, with HC Wainwright & Co. raising its target to $24.00, reflecting analysts' confidence in the company's growth prospects.
See More
